Oxygen deprivation (hypoxia) is a common feature of various human maladies, including cardiovascular diseases and cancer; however, the effect of hypoxia on Ad-based gene therapies has not been described. In this study, we evaluated how hypoxia (1% pO 2 ) affects different aspects of Ad-based therapies, including attachment and uptake, transgene expression, and replication, in a series of cancer cell lines and primary normal cells. We found that hypoxia had no significant effect on the expression or function of the Ad5 attachment (Coxsackievirus and Adenovirus Receptor) and internalization (a v integrins) proteins, nor on the human cytomegalovirus-driven expression of an exogenous gene carried by a replication-incompetent Ad. Viral replication, however, was compromised by hypoxic conditions. Our studies revealed hypoxia-induced reductions in E1A levels that were mediated at the post-transcriptional level. E1A drives cells into the viral replication optimal S phase of the cell cycle; consequently, the combination of reduced E1A protein and hypoxia-induced G1 arrest of cells may be responsible for the lack of efficient viral replication under hypoxic conditions. Consequently, while traditional replication-incompetent Ad-based vectors appear to be viable delivery systems for hypoxia-associated disease indications, our studies suggest that Oncolytic Ads may need additional factors to efficiently treat hypoxic regions of human tumors. Gene Therapy (2005) 12, 902-910.
Introduction
Among the current vectors in clinical trials for gene therapy, Adenovirus (Ad) ranks second only to retroviruses as the gene therapy vector of choice 1 and Adbased gene therapies have been designed to treat a variety of human maladies, including cancer and cardiovascular diseases. These Ad-based treatments are diverse and range from replication-defective viruses expressing therapeutic genes (eg p53) to replicating agents selectively infecting and destroying tumor cells to the exclusion of normal tissues (oncolytic viruses). [2] [3] [4] To be effective, these agents share a need for efficient viral attachment and uptake to target cells, delivering either therapeutic genes (replication defective viruses) or utilizing replication, cytolysis, and spread to neighboring malignant tissues (oncolytic viruses) to generate their therapeutic effect. 5 For oncolytic viruses, additional factors that synergize with or add to the efficacy and/ or safety could be added if necessary. 6 Hypoxia occurs in a variety of human diseases, including myocardial ischemia, critical limb ischemia, stroke and cancer. 7 In patients with critical limb ischemia, hypoxia and associated tissue damage can necessitate amputation. 8 In stroke patients, extended hypoxia can cause cell death beyond the initial insult. 9 For cancer, hypoxia is a prognosticator for poor survival in cancer patients and is thought to select for highly aggressive and radiation-and/or drug-resistant tumors. 10, 11 In addition, hypoxia selects for cells with mutant p53 and defects in apoptosis, 12 and also facilitates angiogenesis needed for the continual growth of cancer cells in the malignant conditions. 13, 14 Therefore, hypoxia is an important component to address in these diseases and a successful viral-based approach to treatment will likely require efficiency in this environment.
Hypoxia could affect adenovirus-based therapies at several levels. For example, cellular gene expression profiles are altered by hypoxia. 15, 16 This may impact levels of cellular proteins necessary for Ad attachment and internalization, affect the ability of promoters (eg HCMV) to function, or alter any number of viral proteins and their associated cellular partners needed to productively replicate and lyse the infected cell. To address these questions, we tested Ad5-based replication-incompetent and -competent viruses in a hypoxic chamber (1% pO 2 ). In our studies, we demonstrate that the expression and function of receptors responsible for Ad attachment and uptake, as well as the expression of an exogenous gene (as measured by an HCMV-driven luciferase reporter gene expression) carried by a replicationdefective Ad, were not compromised by hypoxia. However, viral production and cytolytic activity of the replicating Ad5 virus were altered by these conditions. Importantly, studies of E1A expression revealed a posttranscriptionally mediated reduction in E1A protein expression that, coupled with hypoxia-induced G1 arrest, suggests a mechanism by which hypoxia-induced reduction in viral replication can occur. Our studies suggest that additional strategies will be required for the oncolytic Ad to efficiently treat the hypoxic component of the human tumor.
Results

Validation of the hypoxic chamber
While Ad has been a popular gene therapy vector for a variety of diseases, its ability to infect and express therapeutic genes in the centers of hypoxic tissue is poorly defined. Using a tissue culture chamber, we studied the impact of hypoxia on various aspects of Adbased gene therapies. Unlike a previously published study, 17 our cells were preconditioned, infected, and maintained under hypoxic conditions (1% pO 2 ) throughout the viral infection and during subsequent manipulation. Hif-1a protein was used as a marker for hypoxia, 18, 19 since it has been shown to be upregulated post-translationally under hypoxic conditions 20 and was measured in both cancer cell lines and normal cells used in this study. As seen by anti-Hif-1a immunoblot ( Figure  1 ), Hif-1a protein was increased under hypoxic conditions in the cancer cell lines and the normal cells examined, validating the chamber and these cells for use in this analysis.
Cell surface expression of the Ad attachment and internalization receptors under hypoxic conditions
The infection cycle of adenovirus includes (1) virus attachment and endocytosis; (2) early virus gene expression; (3) viral DNA replication; (4) viral cytolysis and release of mature virions to infect the neighboring tissues. 21 To begin to understand if hypoxia alters any or all of these stages, we examined whether the receptors responsible for viral attachment and uptake are altered in host cells by hypoxia. The Ad5 serotype attaches to the cell by binding to the Coxsackievirus and Adenovirus Receptor (CAR) through the viral fiber protein. 22, 23 Following attachment, viral particles are internalized via integrin (a v b 3/5 )-mediated endocytosis following the interaction of the integrins with the viral penton base protein. [24] [25] [26] [27] Two cancer cell lines (HT29 and DLD1) and two normal cells (human umbilical vein endothelial cells (HUVECs) and human mammary epithelial cells (HMEC)) were cultured under normoxia or hypoxia for 18 h, labeled with antibodies, fixed in paraformaldehyde, and then subjected to flow cytometry analysis for cell surface expression of these virus receptors. For all the cells tested, neither the expression of CAR nor integrin was altered by hypoxia ( Figure 2 ). This was not time dependent as the CAR and integrin levels remained unchanged for up to 96 h of hypoxic treatment (data not shown). These studies demonstrate that hypoxia does not impact the cell surface levels of the CAR or integrin proteins.
Virus attachment and internalization under hypoxia
Although CAR and integrin levels were not altered by hypoxia, some laboratories have reported that Ad can infect cells in a CAR-or integrin a V -independent manner [28] [29] [30] and that alternative integrins 28,31,32 could be used for internalization. To address whether attachment and internalization were altered by hypoxic conditions, cells were exposed to virus under both normoxic and hypoxic conditions and examined at 41C 33 and at 371C to determine attachment and internalization, respectively (see Materials and methods). Infections were performed for 2-3 h, a timeframe that would allow for virus attachment and uptake but not replication of the virus. Viral attachment and internalization were quantified by Q-PCR of Ad5 Hexon DNA and this was normalized to cellular b-actin levels. As seen in Figure 3 , Ad5 attachment was not significantly altered by hypoxia in any of the cells examined (Figure 3a) . Similarly, the endocytosis of Ad5 (by measuring the difference of viral uptake between 37 and 41C) was also unaffected by the conditions of hypoxia (Figure 3b ). Based on these results, the attachment and uptake of Ad5 are not altered by hypoxia. These results, along with the flow cytometry analysis for CAR and integrin expres- Effect of hypoxia on Ad-based gene therapies BH Shen and TW Hermiston sion, support that the levels and function of the Ad attachment and internalization proteins are not altered by hypoxia.
Ad-Luc gene expression under hypoxia
After the uptake of Ad, viral DNA is translocated into the nucleus and early region transcription unit expression initiates. One of these early region transcription units, the E1 region, can be deleted to render the virus replication-incompetent, and to make room for the insertion of an expression cassette coding for a therapeutic gene. 34 Since hypoxia will modulate the gene expression profile of the host cell, 15, [35] [36] [37] we wanted to test whether hypoxia could also impact gene expression from the Ad5 vector. To study this, we used a replicationdefective Ad5 (E1 region deleted) carrying a luciferase reporter gene under the control of the HCMV promoter as our test virus (see Materials and methods). Normoxic or hypoxic cells were infected with Ad5-Luc for up to 48 h and then assayed for luciferase activity normalized to total cellular proteins. We found that both luciferase activity ( Figure 4 , top graph) and expression efficiency ( Figure 4 , efficiency was calculated as a ratio of RLU/ viral DNA under hypoxia to RLU/viral DNA under normoxia) were not significantly altered in HT29, DLD1, and HMEC by hypoxia (P40.1), while there is nearly a five-fold increase in hypoxic HUVECs (P ¼ 0.01). In summary, our results suggest that hypoxia does not compromise the transgene expression from the HCMV promoter. Therefore, replication-incompetent Ad as a vector for gene therapy should be able to effectively infect and express therapeutic genes within hypoxic regions of the target tissue.
Hypoxia alters the production of infectious Ad5
Oncolytic Ads are currently being developed and tested as potential treatments for cancers. [38] [39] [40] [41] [42] To be an effective therapy, the oncolytic virus must infect, replicate, and lyse the target cancer cell and spread to the neighboring malignant tissues in repeated fashion until the tumor cells are eliminated. To investigate the effect of hypoxia on viral DNA replication, we quantified the total viral particles generated by the infection of tumor cells under hypoxic or normoxic conditions. Hypoxic cells were infected with Ad5 at 100 vp/cell and assayed for infectious virus at 3 days post infection by total culture harvest (cells and supernatant). Under these conditions, the number of progeny viral particles was reduced in the hypoxic cells relative to the normoxic cells, with 3.8-to 105-fold more viral particles produced in normoxic cells than hypoxic cells ( Figure 5 ). This suggests that the Figure 4 Effect of hypoxia on gene expression from the replicationdefective Ad5-Luc. Cells were cultured at the indicated oxygen tension and infected with Ad5-Luc at 100 vp/cell for 48 h. Infected cells were detached by trypsin, washed and re-suspended in PBS. A portion of cells were mixed with 5 Â PLB and subjected to luciferase assay. Luciferase activity (RLU) was normalized to total cellular protein. The ratio of luciferase activity under hypoxic to normoxic conditions was graphed (a). Total DNA was extracted from the rest of cells, and the Ad5 Hexon DNA and genomic bactin DNA were quantified by TaqMan. The arbitrary ratio of RLU to viral DNA uptake (transgene expression efficiency) was calculated. The hypoxic effect on viral DNA uptake and on transgene expression efficiceny was also calculated by a hypoxia-to-normoxia ratio (Hx/Nx) (b). Similar results were generated from two additional experiments. Data are shown as mean7s.d. Figure 3 Effect of hypoxia on cellular uptake of Ad5. Cells were pretreated and maintained in normoxia or hypoxia throughout the infection. Cells were infected with Ad5 at 100 vp/cell at 41C to determine attachment (a), or at 371C for internalization (b) for 3 h. The infected cells were washed with PBS and used to prepare the total DNA with the DNeasy kit. The viral hexon DNA uptake was normalized to genomic b-actin DNA. The effect of hypoxia is expressed as the ratio of Ad5 uptake under hypoxic to normoxic conditions. Data represent means of two independent experiments. Figure 5 Effect of hypoxia on Ad5 DNA replication. The indicated hypoxic or normoxic cells were infected with Ad5 at 100 vp/cells for 3 days. Infected cells and medium were harvested and subjected to a plaque assay for quantitation of infectious virus. The virus titer is represented as plaque formation units/ml (PFU/ml). The ratio of viral particles generated under normoxic to hypoxic conditions were calculated and are represented in the figure (number at the bottom). Data represent the means of three independent experiments.
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The cytolytic activity of Ad5 is compromised by hypoxia
The ability of Ad5 to infect, replicate, lyse, spread, and repeat this process is critical for an effective oncolytic virus-based therapy and can be quantified by cell survival assays. Paralleling the Ad5 replication observations outlined in Figure 5 , cell survival of virally infected cancer cells HT29 and DLD1 was significantly increased by hypoxia ( Figure 6 ). In normal cells, Ad5-based cytolysis was also delayed by hypoxia, though to a much greater degree in the primary epithelial HMEC cells relative to the primary endothelial HUVEC cells ( Figure 6 , HMEC and HUVEC). Taken together with results in Figure 5 , our data demonstrate that hypoxia diminishes viral production and delays Ad5-specific cytolysis, with the degree of attenuation dependent upon the cell analyzed.
Hypoxia results in reduced E1A protein levels via a post-transcriptional mechanism
Since the E1A gene products are the first viral genes expressed post infection and are essential for Ad5 replication, we asked whether E1A gene expression is altered under hypoxic conditions. Using Q-RT-PCR, we compared the mRNA levels of E1A gene from cells infected under both hypoxic and normoxic conditions, examining levels of E1A mRNA 8 h post infection. A ratio of E1A mRNA to 18S rRNA was calculated and then normalized to Ad DNA uptake (see Materials and methods). For all cells examined, we found no significant reduction in E1A transcription levels between virally infected normoxic and hypoxic cells (Figure 7a ). Interestingly, for the HUVECs, transcription was actually increased (Figure 7a) . However, at the protein level, significant differences were observed, with levels of E1A protein increased under normoxia for all the cells examined at both 8 (data not shown) and 24 h post infection (Figure 7b) . This is dramatically different from the transcription results, where levels were either not significantly different between normoxic and hypoxic conditions (DLD-1, HT-29, HMEC) or actually increased (HUVEC) (Figure 7a) . The difference in E1A protein levels is not due to infection efficiency, since we have previously shown that similar DNA uptake occurs under both hypoxic and normoxic conditions (Figure 3b ). This suggests that the attenuation of Ad5 replication by hypoxia noted in Figures 5 and 6 could be due to reduced E1A protein.
Hypoxia-induced G1 arrest may synergize with reduced E1A levels to compromise the viral infection
Previous studies have suggested that high E1A protein levels may not be necessary for viral replication in human tumor cells. 43 Consequently, it was not clear that the lower E1A protein levels could completely explain the compromised replication of the Ad5 virus. Hypoxia has been shown to cause G1 arrest in nontransformed cells. 44, 45 Since E1A directs the progression Figure 6 Effect of hypoxia on cytolysis by Ad5. Cells were pretreated with hypoxia (1% pO 2 ) or normoxia (20% pO 2 ) for at least 18 h, then infected with Ad5 at 100 vp/cell (DLD1, HUVEC, HMEC) or 500 vp/cell (HT29) for up to 7 days under the same oxygen tension. The infected cells were assayed with MTS reagents at days 0, 1, 2, 3, 6 and 7 post infection in 371C with 5% CO 2 for 2 h. Viable cells were determined as a percentage of the noninfected controls. Each assay point (n ¼ 4) was tested. Similar results were generated from two independent experiments.
Effect of hypoxia on Ad-based gene therapies BH Shen and TW Hermiston of cells from G0/G1 phase into S phase to provide an environment optimal for viral DNA replication, 46, 47 lowered levels of E1A protein, coupled with the hypoxia-induced cell cycle arrest, could be responsible for lowered levels of viral replication. Subsequent cell cycle analysis demonstrated that most of the cells used in this study were arrested in G1 phase under hypoxia, with the cancer cells showing more G1 arrest than normal cells (Figure 8 ). Interestingly, hypoxia did not affect the cell cycle profile of HUVEC. Consistent with this hypothesis and the role of E1A, Ad5 replication and cytolytic potency were most attenuated by hypoxia in DLD1, HT29, and HMEC cells but least attenuated in HUVEC cells (Figures 5 and 6 ). This suggests that the reduction of Ad5 DNA replication and lytic function under hypoxia conditions may be due to the combination of lowered E1A protein and hypoxia-induced cell cycle G1 arrest.
Discussion
In this study, we analyzed the effects of hypoxia on various aspects of the Ad life cycle. Our data demonstrate that hypoxia did not diminish the cell surface levels of the Ad5 receptors responsible for attachment (CAR) or internalization (integrin a v b 3,5 ) and it did not affect Ad5 binding and uptake by cancer or normal cells. HCMV promoter-mediated gene expression from the replication-incompetent Ad5 also remained unaltered by hypoxia. Our gene expression data from this study are in agreement with previous studies where investigators found that the CMV promoter was efficient under hypoxic conditions both in vitro and in vivo. 48, 49 This suggests that replication-incompetent Ad5 as a gene therapy vector should be able to efficiently infect and express therapeutic genes in regions of hypoxia.
Hypoxia diminished Ad5 replication and cytolytic activity, suggesting that the lytic potential of an oncolytic Ad may not be optimal in the hypoxic component of human solid tumors. The hypoxia-based delay of cytolysis varies in different cell types though the production of total infectious progeny virus was reduced by hypoxia in all the cell types, tumor and normal, tested. It is thus possible that, within the human tumor, the oncolytic virus will perform differently given the regional microenvironment. For example, the oncolytic virus may effectively and safely treat tumor cells in the normoxic portion of the tumor. However, killing of tumor cells under hypoxic conditions may be delayed, requiring higher doses to effectively treat this component of the tumor, doses that may lead to unwanted toxicity in neighboring infected normal tissues that are still under normoxic conditions. Since tumor hypoxia is associated with poor prognosis, the ability of the oncolytic virus to eradicate these cells may be important to an effective replicating virus-based cancer therapy.
Current efforts to address the hypoxic component of human tumors have centered on promoter-driven gene expression of either a key viral protein (E1A) or a therapeutic gene (BAX). An engineered replicating Ad with E1A under the control of hypoxia responsive elements (HRE) demonstrate reduced cytolytic activity under hypoxia relative to the wild-type parents d1309, Effect of hypoxia on Ad-based gene therapies BH Shen and TW Hermiston and cytolytic activity was restricted to the hypoxic component of the tumor. 17 Our data would suggest that E1A protein, not transcription, is affected by hypoxia. Whether the lowered potency under hypoxia relative to the wild-type virus in the HRE-Ad study occurs due to the combination of lowered E1A protein levels and cellular G1 arrest hypothesis suggested by our studies is unclear and additional factors may be involved.
In addition to altering Ad gene expression, attempts have been made to increase apoptosis by introducing an HRE-controlled proapoptotic gene (such as BAX). 50 A potential drawback to this approach is that BAX-induced cell death may destroy the hypoxic cells prior to viral replication and the development of infectious progeny virus. However, ample replicating virus being expressed in the normoxic component of the tumor, and BAX expressed exclusively in the hypoxic component, may represent a viable approach to treat these two components of the human tumor. Ultimately, clinical testing will be needed to test this approach.
Ad replication is attenuated under hypoxic conditions and our studies clearly suggest that initial attachment and uptake do not play a role. Ad replication is attenuated in part due to hypoxia-induced cell cycle arrest. Hypoxia has been shown to induce G1 arrest 51 and this may create a challenging environment for the infectious Ad, which has been shown to replicate optimally in S phase cells. 52 The human Ad E1A region has well-defined functions to drive the cell out of the G1 phase, however this capacity may be compromised by the reduced levels of E1A protein seen under hypoxic conditions. Thus, Ad replication is attenuated by the combination of hypoxia-induced G1 arrest and hypoxiainduced EIA protein reduction. It is important to note that, in some oncolytic Ads, functional areas of the E1A protein critical to inducing cell cycle progression are altered. [53] [54] [55] Consequently, these viruses will be, presumably, further attenuated in the hypoxic regions than our wild-type Ad5 test subject. Given the association of hypoxia with solid tumors and its negative prognostic value, our studies suggest that the hypoxic component of human tumors may not be effectively treated by many current Ad5-based oncolytic Ads. Thus, new oncolytic Ad strategies will be needed to more effectively treat this component of human tumors.
Materials and methods
Cells and tissue culture conditions
HEK293 and cancer cell lines (HT29 and DLD1) were purchased from the ATCC, and cultured in the medium recommended by the vendor. Primary HUVECs and HMEC were purchased from Cambrex (East Rutherford, NJ, USA), and cultured in specially formulated medium as supplied by the vendor.
Cells were split at least 4 h before hypoxic treatment. The hypoxic chamber (Coy laboratories, Grass Lake, MI, USA) was maintained with a gas supply of 95% nitrogen and 5% CO 2 . All the hypoxic assays were performed under 1% pO 2 .
Western blot analysis
Cells grown under hypoxic or normoxic conditions were harvested by cell scrapers, and lysed in ELB buffer with protease inhibitors (50 mM Hepes, pH 7.4, 250 mM NaCl, 0.1% NP-40, 10 mM b-glycerophosphate, 1 mM NaF, 1 mM EDTA, 1 mM DTT). Protein was quantified by BCA kit (Pierce, Rockford, IL, USA) to ensure that equal amounts of protein were loaded. Whole cell extracts were separated by SDS-PAGE, and cellular proteins were transferred onto PVDF membranes (Invitrogen, Carlsbad, CA, USA). Western blot was carried out according to the protocol provided with the ECL-plus detection kit (Amersham, Piscataway, NJ, USA). Anti-Hif-1a was purchased from BD Pharmingen (San Diego, CA, USA), anti-Ad2 E1A (crossreacts with both Ad2 and Ad5 E1A) from Exalpha Biologicals (Boston, MA, USA), and anti-bactin from Sigma (St Louis, MO, USA). Anti-E1A Western blots was scanned and quantified using the Gel/Chem doc program QuantityOne (Bio-Rad, Hercules, CA, USA). The quantitation of the hypoxic effect on E1A protein levels was calculated as a ratio of the scanned signals of E1A protein under normoxic and hypoxic conditions.
Viruses and viral production
Ad5 and Ad5-Luc were generated in HEK293 cells, and viral particles were purified using a CsCl gradient and quantified by OD260. 56 Replication-incompetent Ad5-Luc was generated by replacing an FGF4 gene expression cassette with a CMV-Luciferase expression cassette, using homologous recombination in Escherichia coli as described. 57 This virus has a complete deletion of the E1 region and partial deletion of the E3 region.
Flow cytometry
Cells were split into 10-cm dishes and cultured under either normoxic (20% pO 2 ) or hypoxic (1% pO 2 ) conditions for 418 h. The next day, cells were re-suspended in a PBS-based cell dissociation buffer (Invitrogen, Carlsbad, CA, USA), and washed in PBS without Mg 2+ /Ca 2+ (Invitrogen, Carlsbad, CA, USA). Cells (10 6 ) were incubated with primary antibody (listed below) on ice for 1 h, and washed with FACS buffer (1% BSA in PBS buffer) twice. Cells were then incubated with FITC-goatanti-mouse IgG(H+L) (1.5 mg/ml, FI-1000, Vector) for 430 min, and then washed with cold FACS buffer twice. Labeled cells were scanned by FACS Calibur (Becton Dickinson, CA, USA). The fluorescence intensity is the ratio of geometric means from cells labeled with antibody to those with a matched control isotype. The hypoxic effects were represented by the ratio of fluorescence under hypoxic to normoxic conditions.
Mouse anti-human CAR supernatant from hybridoma cell line (RmcB, 4 mg/ml, ATCC) and mouse anti-human Integrin a v (CD51, Clone M9, 0.2 mg/ml, MAB1980, Chemicon, Temecula, CA, USA) were diluted at 1:100 and 1:50, respectively, in FACS buffer (1% BSA in PBS without Mg 2+ /Ca 2+ ). Mouse IgG (H+L) (1 mg/ml, Vector Laboratories, Burlingame, CA, USA) diluted at 1:100 was used as an isotype control. FITC-goat-anti-mouse IgG(H+L) (1.5 mg/ml, FI-1000, Vector Laboratories) was used as the secondary antibody at a 1:200 dilution.
Nuclei were prepared and stained with propidium iodide (PI) by using Cycle-Test kit (BD Biosciences). DNA was analyzed by FACS Calibur (BD Biosciences). The percentage of cells in G0/G1, S or G2/M phase was calculated by using ModFit LTt 2.0 software (Verity Software House Inc., Topsham, ME, USA).
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MTS assay
Cells were split in complete medium (10% FBS) into 96-well plates, and maintained under hypoxic or normoxic conditions for 418 h prior to infection. On the day of infection, medium was removed and the same amount of medium with 2% FBS containing the described amounts of viral particles were incubated with cells for 3 h to 7 days. Cell viability was measured daily by the MTS assay to follow Ad-specific killing. MTS assays were carried out by adding 20 ml of the CellTiter96 Aqueous Nonradioactive cell proliferation assay kit (Promega, Madison, WI, USA) to each well and the plates were incubated at 371C with 5% CO 2 for 2-3 h. Hypoxic plates were always incubated in the hypoxic chamber for the duration of the experiment. OD490 readings were generated using SPECTRAmax s microplate spectrophotometer (Molecular Device, Sunnyvale, CA, USA), and data analysis was performed using SOFTMax software package. The cell viability was measured as a percentage of viable cells remaining in the infected wells against viable cells remaining in the noninfected wells. Each point was performed in quadruplet for every experiment, and each experiment was repeated at least twice.
Student t-tests were performed to determine whether differences seen between the hypoxic and normoxic groups were statistically significant. Statistical significance was accepted when Po0.05.
Quantification of the attachment and internalization of Ad by Q-PCR
After an 18-h incubation under hypoxic or normoxic conditions, cells in six-well plates were infected with Ad5 at 100 vp/cell for 2 h, at 41C (for attachment) or 371C (for attachment and endocytosis). Then cells were washed with PBS twice, and subjected to total DNA extraction by the DNeasy kit (Qiagen, Valencia, CA, USA).
Ad5 Hexon and genomic b-actin DNA levels were quantified by real-time PCR. The Hexon primers were REC1U (CTTCTCTACGCCAACTCCGC), REC1L (GCA GGTACACGGTTTCGATGA), and the probe for Hexon was REC1P (TTGAGGTGGATCCCATGGACGAGC). A b-actin primer/probe set for human genome DNA was purchased from Applied Biosystems (Foster City, CA, USA). 2 Â Taqman universal master mix (Applied Biosystems) was added to DNA template from DNeasy preparation (Qiagen), primers and probe. The thermocycler was set to an initial denaturation at 951C for 10 min, and then followed by 40 cycles of amplification (951C for 15 s and 601C for 1 min). Real-time PCR was recorded through ABI PRISM s 7700 Sequence Detection System (Applied Biosystems). Data were analyzed with Sequencer software. Purified Ad5 DNA or human genome DNA (Applied Biosystems) was used as a standard. The virus uptake is represented by the ratio of Hexon to Actin (V ¼ Hexon/Actin). The ratio at 41C (V 4 ) represents the attachment of virus particles. The internalized virus is quantified by subtracting the ratio at 41C from that at 371C (V 37 ). Hypoxic effects are represented by the ratio of DNA uptake under conditions of hypoxiac to normoxia:
Virus titer assay
Various cell types were infected with Ad5 under normoxic or hypoxic conditions. At 3 days post infection, cells and culture supernatant were subjected to three cycles of freeze/thaw to release the viral particles inside the cell. Cellular debri was removed by centrifuging at 3000 rpm for 5 min and the cleared final supernatant was titered for infectious virus by plaque assay.
HEK293 cells were seeded in six-well plates at a density of 2.25 Â 10 5 cells/well. After 24 h, medium was removed and cells were incubated with 100 ml of the designated serially diluted viral stock plus 500 ml of 2% medium (DMEM with 2% FBS) for 2 h. The supernatant was then removed and the infected cells were overlaid with 1% agarose in 2% FBS and incubated at 371C. Plaques were counted after 1 week.
Luciferase assay for Ad5-Luc
Pretreated cells on a 12-well plate were infected by Ad5-Luc at 100 vp/cell for 48 h at 371C. Cells were then trypsinized and washed with PBS twice. Total cells were re-suspended in 250 ml of PBS. In all, 50 ml of cell suspension was aliquoted and analyzed for luciferase activity and 200 ml was aliquoted for a DNA uptake assay. For luciferase activity, the 50 ml aliquot was mixed with 1/4 volume of Passive Lysis Buffer (Promega), and incubated at room temperature for 15 min to lyse the cells. Cell lysates were subjected to centrifugation at the maximum speed for 5 min. The supernatant was used for luciferase assay (Promega) and protein quantification using a BCA kit (Pierce, Rockford, IL, USA).
Quantification of E1A transcription by Q-RT-PCR
Cells were infected with Ad5 at 100 vp/cell for 4-8 h followed by 2 Â PBS wash. Total DNA was purified by using the DNeasy kit with RNase A digestion (Qiagen) and analyzed for DNA uptake (D Hexon /D Actin ). Total RNA was extracted by using the RNeasy kit with in-gel DNase digestion (Qiagen). RT-PCR was performed by mixing total RNA with Taqman one-step RT-PCR master mix in the presence of RNase inhibitor, E1A probe and primers (Applied Biosystems). Reverse transcription was performed at 481C for 30 min, and then the PCR reaction was performed as described previously in the DNA uptake assay.
E1A probe and primers were Ad5E1A750P (CAGCC GGAGCAGAGAGCCTTGG), Ad5E1A750F (TTCCCGG CAGCCCG) and Ad5E1A750R (ACAAGGTTTGGCATA GAAACCG). The probe and primer set for human 18S rRNA was purchased from Applied Biosystems as an internal control. To quantify E1A transcription, we first calculated the RNA ratio of E1A to 18S (R E1A /R 18S ). An arbitrary unit for E1A transcription (AU E1A ) was calculated after normalized to DNA uptake: AU E1A ¼ ðR E1A =R 18S Þ=ðD Hexon =D Actin Þ:
Rhonda Humm, Jean MacRobbie and Eileen PauloChrisco for providing cell lines; Richard N Harkins and Gabor Rubanyi for critical reading of the manuscript. This work is supported by a PFO fellowship from Schering AG.
